Search
Showing results for "early lung health"
On this Research Impact page, we list stories helping demonstrate how we collaborate with other leaders, innovators, communities, and international stakeholders to ensure excellent research results. The better our results, the better the chances of research making a real difference.
Research
The Platform trial In COVID-19 vaccine priming and BOOsting (PICOBOO) booster vaccination substudy protocolCoronavirus-2019 (COVID-19) vaccination in Australia commenced in February 2021. The first vaccines recommended for use were AZD1222 and BNT162b2, both delivered as a two-dose primary schedule. In the absence of sustained immunity following immunisation, recommendations for booster vaccination have followed. It is likely that periodic boosting will be necessary for at least some Australians, but it is unknown what the optimal booster vaccines and schedules are or for whom vaccination should be recommended.
News & Events
Research to help identify which children will develop asthma and to design more specific asthma treatments supported by Federal Government fundingResearch focussed on identifying which children will develop asthma, and developing more specific asthma treatments, has been supported by the National Health and Medical Research Council’s (NHMRC) Ideas Grants announced by the Federal Government on 14 December 2022.
Research
TESTOV PneumoChristopher Elke Jennifer Tom Blyth Seppanen Kent Snelling MBBS (Hons) DCH FRACP FRCPA PhD BSc PhD RN BMBS DTMH GDipClinEpid PhD FRACP Centre Head,
News & Events
The Impact of Poverty - interview with Steve ZubrickGrowing up poor is about more than just the size of your bank account. Read the new CoLab Impact of Poverty Evidence Report.
Our team uses AI to quickly analyse large amounts of genetic data to help discover alternate medications and improve existing treatments.
Research
The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second boosterPICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. We report data for second boosters among individuals 50-<70 years old primed with AZD1222 (50-<70y-AZD1222) until Day 84.
A decade long partnership with Wesfarmers Ltd. and the Wesfarmers Centre of Vaccines and Infectious Diseases has led to world-class paediatric research and important collaborations fuelling the Centre’s trajectory towards easing the burden of infectious diseases.
As well as ORIGINS long-term core research, there are a number of clinical trials, early interventions and shorter-term research studies that sit within ORIGINS. Known as sub-projects, these studies look at multiple aspects of child and family health and development.
Dr Anthony Bosco, Professor Steve Stick, Professor Andrew Whitehouse, Dr Raelene Endersby and Dr Luke Garratt know how fortunate they are to have